Myeloma UK creates COVID-19 Information Hub 

Myeloma UK have developed an information hub to help keep patients up to date with the latest news on COVID-19. The COVID-19 Information Hub is a one stop shop for information about the COVID-19 pandemic and how it is affecting patients’ treatment and care. The Hub is being regularly updated with the latest news and guidance from the UK Government…

Sarah and Ira and ASH 2019

Highlights from the American Society of Haematology 2019

The 61st American Society of Hematology Annual Meeting (ASH) took place on 7-10 December in Orlando, Florida. It was attended by over 30,000 scientists and clinicians from around the world and covered around 6,000 topics with over 700 myeloma abstracts. Here are some of our highlights from this year’s meeting. Myeloma XI There were five…

ASH 2019

Myeloma UK funded research presented at ASH 2019

  The 61st American Society of Hematology Annual Meeting (ASH) took place on 7-10 December in Orlando, Florida. Our Director of Research Sarah McDonald and Director of Healthcare Advocacy Services Ira Laketic-Ljubojevic attended to learn about the latest myeloma research and see the progress from Myeloma UK funded research. Results from research part-funded by Myeloma UK, the…

Review of drug approval

Update on NICE review of drug approval methods

The way evidence is used to approve new treatments for use on the NHS is set to change, under a review being carried out by the National Institute for Health and Care Excellence (NICE). The review of methods, running throughout 2020, is an opportunity to address some of the challenges in approving treatments: for example, ensuring…

Sarah MacDonald - New Director of Research, Myeloma UK

Myeloma UK introduces new Director of Research

This month Myeloma UK welcomed Sarah McDonald as our new Director of Research. In her new role, Sarah will be responsible for both the patient advocacy and research teams. She will play a key role in advancing our patient advocacy work and health services, translational, and clinical research programmes to strengthen the impact of Myeloma…

Picture of bacteria

Reducing serious infection in newly diagnosed myeloma patients by antibiotic prophylaxis: results from the TEAMM trial

Serious infection is one of the largest contributors to early mortality in myeloma. The use of antibiotic prophylaxis for newly diagnosed patients starting treatment offers an opportunity to tackle this early complication however the potential for antibiotic resistance, side effects and healthcare associated infections needs to be carefully considered. Last month Prof Mark Drayson, Consultant…


New international guidelines recommend the use of whole-body imaging in monoclonal plasma cell disorders

New recommendations from the International Myeloma Working Group (IMWG) on the use of imaging methods in monoclonal plasma cell disorders were recently published in The Lancet Oncology. (1) Overall, the guidelines recommend that more sensitive imaging techniques, such as whole-body CT and MRI, be introduced generally into clinical practices for the diagnosis and management of…